DEVOURED
Why haven't organoids solved all of drug discovery?
Organoids remain a promising but inconsistent tool for drug discovery due to significant reproducibility issues and a lack of systemic biological integration.
What: Organoids, 3D cell aggregates used for modeling human tissue, currently suffer from batch-to-batch variability in substrates like Matrigel and technical inconsistency across laboratories. They lack vascularization, immune systems, and reliable aging markers.
Why it matters: The reliance on fetal-state cells and the absence of systemic human physiology like blood flow make organoids poor predictors for many drug interactions, despite their utility in localized cell studies.
Deep dive
- Reproducibility: Matrigel, derived from mouse sarcoma, is chemically heterogeneous, leading to inconsistent organoid growth.
- Cell Variability: Pluripotent stem cell (PSC) lines exhibit "primed" vs. "naive" state differences that alter tissue architecture.
- Vascularization: Lack of functional blood vessels creates necrotic cores, limiting size and metabolic drug studies.
- Immune Absence: Incompatibility between immune-cell media and organoid media prevents studying inflammatory drug responses.
- Aging: Organoids generally mirror fetal developmental stages, complicating studies of adult-onset neurodegenerative or metabolic diseases.
Decoder
- Organoid: 3D self-organizing structures derived from stem cells that recapitulate organ-specific cell types and functions.
- PSC (Pluripotent Stem Cell): Cells capable of differentiating into any cell type in the body.
- Matrigel: A gelatinous protein mixture secreted by mouse tumor cells, used as a scaffold for cell growth.
- Necrotic core: A region in the center of an organoid where cells die due to lack of oxygen and nutrients caused by the absence of blood vessels.
Original article
Full article content is not available for inline reading.
Explore all 56 articles in today's digest
Fresh dev news, AI-digested daily. Never miss a trend at devoured.fyi